Of @ screened patients , @ were eligible and were randomly assigned to the four treatment groups : evolocumab @ mg every @ weeks ( n = @ ) , evolocumab @ mg monthly ( n = @ ) , placebo every @ weeks ( n = @ ) , or placebo monthly ( n = @ ) .